FLT1 and neoplasm: About 83%, 87%, and 77% of CRC patients aged ≥65 had VEGFR-1-positive, VEGFR-2-positive, and VEGFR-3-positive tumor tissues and this was significantly more than the 51%, 67%, and 59% of CRC patients aged <65.